In conclusion, ANP prevents early AS progression by reducing both T lymphocyte inflammation and arterial wall inflammation, without hyperlipidemia, and it is potentially equivalent to simvastatin based on these effects. The gene discussed is NPPA; the disease is hyperlipidemia.